ObjectiveTo explore more effective and lower expensive approach for aplastic anemia(AA).Methods A prospective,randomized clinical trial was conducted to determine whether the outcome of AA patients treated with the combination of securinine plus anisodamini dripping in bone marrow(therapy group)was better than that with anisodamini alone dripping in vein(control group).Results The cure remission rate(83.3%) and the response rate(94.4%) of therapy group were significantly higher than that of control group(11%,55.6%, P